Showing 161 - 180 results of 1,574 for search '"kinase"', query time: 0.07s Refine Results
  1. 161

    Determinants Present in the Receptor Carboxy Tail Are Responsible for Differences in Subtype-Specific Coupling of β-Adrenergic Receptors to Phosphoinositide 3-Kinase by Julie Simard, Matthieu Boucher, Rachel Massé, Terence E. Hébert, Guy Rousseau

    Published 2009-01-01
    “…An agonist-occupied β2-adrenergic receptor (β2-AR) recruits G protein receptor kinase-2 (GRK2) which is recruited to the membrane. …”
    Get full text
    Article
  2. 162

    Protein Kinase A Is Involved in Neuropathic Pain by Activating the p38MAPK Pathway to Mediate Spinal Cord Cell Apoptosis by Yajun Deng, Liang Yang, Qiqi Xie, Fengbiao Yang, Guoqiang Li, Guangzhi Zhang, Shaoping Li, Zuolong Wu, Jing Wang, Xuewen Kang

    Published 2020-01-01
    “…This study is aimed at investigating protein kinase A (PKA) expression in neuropathic pain and its possible mechanisms of involvement. …”
    Get full text
    Article
  3. 163
  4. 164
  5. 165

    Casein Kinases 2-dependent phosphorylation of the placental ligand VAR2CSA regulates Plasmodium falciparum-infected erythrocytes cytoadhesion. by Dominique Dorin-Semblat, Jean-Philippe Semblat, Romain Hamelin, Anand Srivastava, Marilou Tetard, Graziella Matesic, Christian Doerig, Benoit Gamain

    Published 2025-01-01
    “…Here, we aimed to identify the kinases mediating this phosphorylation. We report that Human and Plasmodium falciparum Casein Kinase 2α are involved in the phosphorylation of the extracellular region of VAR2CSA. …”
    Get full text
    Article
  6. 166

    Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib by Vineeth Sukrithan, Lisa Kim, Jennifer A. Sipos, Ashima Goyal, Ye Zhou, Daniel Addison, Manisha Shah, Bhavana Konda, Ajay Vallakati

    Published 2023-01-01
    “…The multitargeted tyrosine kinase inhibitor lenvatinib has demonstrated significant improvements in progression-free survival in RAIR thyroid cancers compared to placebos. …”
    Get full text
    Article
  7. 167

    Imatinib Resistance in Chronic Myeloid Leukemia Associated with a D363G BCR::ABL1 Kinase Domain Mutation by Stephen E. Langabeer, Stuart Macleod, Úna Bhreathnach, Kamal Fadalla

    Published 2023-01-01
    “…Acquired resistance to tyrosine kinase inhibitors (TKIs) remains a therapeutic challenge in the treatment of chronic myeloid leukemia (CML). …”
    Get full text
    Article
  8. 168
  9. 169
  10. 170
  11. 171

    Silent Neuroleptic Malignant Syndrome: A Case Report of Atypical Antipsychotic Induced Elevation of Creatinine Kinase and Altered Mental Status by Amber N. Edinoff, Hamza Mohammad-Amin, Amira S. Odisho

    Published 2022-08-01
    “…Two days after medication initiation, the patient's mentation was altered and he appeared confused with an elevated creatine kinase (CK) at 7101. Medications were held and CK normalized with IV fluids. …”
    Get full text
    Article
  12. 172
  13. 173
  14. 174
  15. 175

    Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis. by Konstantinos Ouranos, Diana V Avila, Evangelia K Mylona, Athanasios Vassilopoulos, Stephanos Vassilopoulos, Fadi Shehadeh, Eleftherios Mylonakis

    Published 2024-01-01
    “…The goal of our study was to calculate the pooled cumulative incidence and risk of infection in patients with RA treated with Janus kinase inhibitors (JAKi). The PubMed and EMBASE databases were queried for randomized controlled trials comparing patients with RA treated with JAKi (upadacitinib, baricitinib, tofacitinib, peficitinib, or filgotinib), defined as the treatment group, compared with control subjects, defined as participants receiving placebo or treatment regimen that was similar to that of participants in the treatment group, with the exception of JAKi. …”
    Get full text
    Article
  16. 176

    Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: where do we stand and what may be the future? by Beatrice Maranini, Roberta Foti, Moustapha Taha, Veronica Venturelli, Andrea Lo Monaco, Marcello Govoni

    Published 2025-01-01
    “…Over the past few years, Janus kinase inhibitors (JAKis) have been reported to have promising efficacy in the treatment of active RA, but recent concerns have been raised about their safety profile, namely malignancy and cardiovascular disease, limiting their use to certain patient categories. …”
    Get full text
    Article
  17. 177

    Involvement of different protein kinases and phospholipases A2 in phorbol ester (TPA)-induced arachidonic acid liberation in bovine platelets by M. Lehr, K. Griessbach

    Published 2000-01-01
    “…The effect of various phospholipase A2 and protein kinase inhibitors on the arachidonic acid liberation in bovine platelets induced by the protein kinase activator 12-O-tetradecanoylphorbol–13-acetate (TPA) was studied. …”
    Get full text
    Article
  18. 178

    Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder by Syouichi Katayama, Noriyuki Sueyoshi, Tetsuya Inazu, Isamu Kameshita

    Published 2020-01-01
    “…Cyclin-dependent kinase-like 5 (CDKL5, also known as STK9) is a serine/threonine protein kinase originally identified in 1998 during a transcriptional mapping project of the human X chromosome. …”
    Get full text
    Article
  19. 179

    Activating Mutation (V617F) in the Tyrosine Kinase JAK2 is Absent in Locally-Confined or Castration-Resistant Prostate Cancer by Lei Gu, Xian-Hua Zhu, Tapio Visakorpi, Kalle Alanen, Tuomas Mirtti, Tina Bocker Edmonston, Marja T. Nevalainen

    Published 2010-01-01
    “…The receptor-associated tyrosine kinase Jak2 is a known key activator of Stat5a/b in prostate cancer cells in response to ligand stimulation. …”
    Get full text
    Article
  20. 180